ArticleAmerican journal of ophthalmology case reports2025
Treatment of severe dry eye following acoustic neuroma surgery with eyelid androgen gel application.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a case of recalcitrant dry eye disease caused by acoustic neuroma and subsequent microsurgery. Observations: A 51-year-old female presented with refractory unilateral (right eye) severe dry eye disease (DED). The patient had a history of right acoustic neuroma with surgical excision 14 years prior. With normal eyelid closure, the patient reported persistent dry eye symptoms despite use of several tear substitutes and ointments. The patient was a subject in a clinical trial, and was found to be in the active treatment arm following unmasking. The patient had been dosed with a topical eyelid application of testosterone 4.5 % wt./wt. gel twice per day for 4 weeks and followed up to 8 weeks after discontinued drug application. Dry eye symptoms were significantly improved and brought to near normal range (Ocular Surface Disease Index (OSDI) < 13). Tear break up time, meibomian secretion quality, and tear osmolarity were also improved to near normal levels in both the affected and unaffected eyes. In the affected eye, ocular surface staining and Schirmer result were improved from baseline at week 12, but remained below normal values. Conclusions and importance: The recalcitrant DED secondary to an acoustic neuroma and subsequent microsurgery resection was due to injury of the nervus intermedius, resulting in aqueous deficient DED. Topical testosterone treatment on the eyelids ameliorated the DED by improving symptoms and restoring some clinical signs to near-normal levels, suggesting that this may potentially be a new treatment approach in aqueous deficient dry eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.